Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetic Subjects: A randomized controlled crossover trial by Ma, Yingying et al.
Effects of Walnut Consumption on
Endothelial Function in Type 2 Diabetic
Subjects
A randomized controlled crossover trial
YINGYING MA, MD, RVT
VALENTINE YANCHOU NJIKE, MD, MPH
JOHN MILLET, BA
SUPARNA DUTTA, MD, MPH
KIM DOUGHTY, BS
JUDITH A. TREU, MS, RD
DAVID L. KATZ, MD, MPH
OBJECTIVE — To determine the effects of daily walnut consumption on endothelial func-
tion, cardiovascular biomarkers, and anthropometric measures in type 2 diabetic individuals.
RESEARCH DESIGN AND METHODS — This study was a randomized, controlled,
single-blind, crossover trial. Twenty-four participants with type 2 diabetes (mean age 58 years;
14 women and 10 men) were randomly assigned to one of the two possible sequence permuta-
tions to receive an ad libitum diet enriched with 56 g (366 kcal) walnuts/day and an ad libitum
diet without walnuts for 8 weeks. Subjects underwent endothelial function testing (measured as
ﬂow-mediated dilatation [FMD]) and assessment of cardiovascular biomarkers before and after
each 8-week treatment phase. The primary outcome measure was the change in FMD after 8
weeks. Secondary outcome measures included changes in plasma lipids, A1C, fasting glucose,
insulin sensitivity, and anthropometric measures.
RESULTS — Endothelial function signiﬁcantly improved after consumption of a walnut-
enriched ad libitum diet compared with that after consumption of an ad libitum diet without
walnuts(2.21.7vs.1.21.6%;P0.04).Thewalnut-enricheddietincreasedfastingserum
glucose and lowered serum total cholesterol and LDL cholesterol from baseline (10.0  20.5
mg/dl, P  0.04; 9.7  14.5 mg/dl, P  0.01; and 7.7  10 mg/dl, P  0.01, respectively),
although these changes were not signiﬁcant compared with those for an ad libitum diet without
walnuts. There were no signiﬁcant changes in anthropometric measures, plasma A1C, and
insulin sensitivity.
CONCLUSIONS — A walnut-enriched ad libitum diet improves endothelium-dependent
vasodilatation in type 2 diabetic individuals, suggesting a potential reduction in overall cardiac
risk.
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D
iabetes and its complications are
majorcausesofmorbidityandmor-
tality in the U.S. and contribute
substantially to health care costs (1). Men
and women with type 2 diabetes have
three- and ﬁvefold higher cardiovascular
mortality, respectively, than the nondia-
betic population (2). The Nurses Health
Study (3) showed an inverse association
between nut consumption and the risk of
type 2 diabetes. Although intervention
studies with nuts have not demonstrated
considerablebeneﬁtsfordiabeticindivid-
uals in terms of long- or short-term glyce-
mic control, nuts may help diabetic
individuals depress postprandial glyce-
mia, reduce postprandial oxidative stress,
and improve blood lipid proﬁles (4). Ep-
idemiological and clinical trial evidence
hasconsistentlydemonstratedthebeneﬁ-
cial effects of nut consumption on risk
factorsassociatedwithcoronaryheartdis-
ease(5,6).Numerousstudieshaveshown
thatdietsrichinpolyunsaturatedfattyac-
ids (PUFAs) can signiﬁcantly reduce
bloodLDLcholesterollevels,decreasethe
total cholesterol–to–HDL cholesterol ra-
tio, and help achieve optimal fat con-
sumption without adverse effects on total
fat or energy intake (7,8). Walnuts have a
higher content of PUFAs than do other
nuts, including -linolenic acid, which
may give walnuts additional antiathero-
genic properties. In a review of clinical
trials, it was found that walnut consump-
tionintheamountoftwotothreeservings
per day consistently decreased total cho-
lesterol and LDL cholesterol (7).
Walnut ingestion has been shown to
improve endothelial function in patients
with hypercholesterolemia (9,10). De-
spite the prevalence of endothelial dys-
function in diabetes and evidence that
walnut consumption may improve both
endothelial function and biomarkers of
cardiovascular disease risk in patients
with hypercholesterolemia, no studies
have investigated the effect of walnut in-
take on endothelial function in type 2
diabetes. Therefore, this study was per-
formed to investigate the effects of a wal-
nut-enriched diet on endothelial function
and other cardiovascular risk factors in
type 2 diabetic individuals.
RESEARCH DESIGN AND
METHODS— Twenty-four partici-
pants with type 2 diabetes were recruited
fromtheLowerNaugatuckValleyinCon-
necticut through ﬂyers and newspaper
advertisements. Those responding (n 
129) were prescreened using a semistruc-
turedtelephoneinterview.Eligiblepartic-
ipants had a clinical diagnosis of type 2
diabetes for at least 1 year but no more
than 5 years, were nonsmokers, were
aged30–75years,hadserumglucoselev-
els and medication doses that had been
stable for 3 months, and were not cur-
rently receiving insulin therapy. Exclu-
sion criteria included current use of
vasoactive medications or supplements,
current eating disorder, known athero-
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pregnancy, restricted diet, allergy to wal-
nuts or other nuts, and use of lipid-
lowering or antihypertensive medications
unless stable condition with medication
for at least 3 months, and willingness to
refrain from taking medication for 12 h
beforeassessment.Thosepassingthetele-
phone screening (n  38) underwent a
clinical screening examination consist-
ing of height, weight, BMI, and blood
pressure measurements and laboratory
testing including serum lipids, fasting
serum glucose, fasting serum insulin,
and plasma A1C. The study protocol
and consent form were approved by the
Grifﬁn Hospital (Derby, CT) Institu-
tional Review Board. Signed informed
consent was obtained from all study
participants, and all participants re-
ceived monetary compensation for their
participation. Subject participation and
ﬂow are shown in Fig. 1.
This study was a randomized, con-
trolled, single-blind, crossover clinical
trial. All participants ﬁrst underwent a
4-weekrun-inperiodtoallowfordietand
weight stabilization, during which partic-
ipants discontinued eating walnuts and
taking vasoactive over-the-counter medi-
cationsandsupplements.Aftertherun-in
period, participants (n  24) were ran-
domly assigned to one of two possible
permutations of a walnut-enriched ad li-
bitum diet and an ad libitum diet without
walnuts for 8 weeks. Treatment assign-
mentswereseparatedbyan8-weekwash-
out period.
During the walnut-enriched diet
treatment period, participants consumed
56 g of shelled, unroasted English wal-
nuts per day. Participants were given an
8-week supply of walnuts and were in-
structed to consume the walnuts as a
snack or with a meal. Participants were
askedtobringtheiremptypackagesatthe
end of the walnut-enriched diet period.
Participantscompleted3-daydietrecords
during the study. The 3-day diet records
weredoneonceduringtheoriginalrun-in
period, once during the dietary period,
and once during the washout period. Par-
ticipantswereinstructedtomaintaintheir
baseline medications, supplements, and
physical activity levels throughout the
study. To ensure that weight remained
constant during the walnut-enriched diet
period, participants were counseled by a
registered dietitian on strategies for isoca-
lorically substituting walnuts for other
foods in the diet but were instructed to
otherwise continue with their usual di-
etary patterns. Compliance with treat-
ment and dietary patterns was assessed
from the diet records.
During each visit, participants under-
went endothelial function testing in the
morning after a minimum 8-h overnight
fast. Weight, height, blood pressure, se-
rum lipids, fasting serum glucose, fasting
serum insulin, and plasma A1C were also
measured. Baseline data were collected
for all outcome measurements at the be-
ginning of the ﬁrst treatment period.
Figure 1—Flow chart for subject participation.
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artery reactivity studies
Endothelial function was measured non-
invasively in the right brachial artery by a
high-frequency ultrasound scanning ma-
chine (Sonos 4500; Phillips Medical Sys-
tems, Andover, MA) in accordance with
published guidelines (11) and our previ-
ous endothelial function studies. In brief,
subjects were required to rest in a quiet,
temperature-controlled, softly lit room
for 15 min before scanning was initiated.
The right brachial artery was imaged lon-
gitudinally, 2–5 cm above the antecubital
fossa,byanexperiencedregisteredvascu-
lar technologist who was blinded to the
treatmentassignments.Arestingscanwas
performed, and arterial ﬂow velocity was
measured. An occluding cuff placed on
the upper arm was inﬂated to a pressure
of 50 mmHg for 5 min and rapidly de-
ﬂated to induce reactive hyperemia. Bra-
chial artery scans were acquired on
magnetic optical disk continuously be-
tween 30 and 180 s after cuff deﬂation,
including a repeated ﬂow-velocity mea-
surement during the ﬁrst 15 s after cuff
release.Brachialarterydiameterswerean-
alyzedbycommerciallyavailablesoftware
(Brachial Analyzer; Medical Imaging Ap-
plication, Iowa City, IA). Dilatation from
baseline was measured at 50–80 s after
cuff deﬂation to assess endothelium-
dependent vasodilatation. To test in-
traobserver reliability, a random sample
of20brachialarteryreactivitystudieswas
read by the same registered vascular tech-
nologistforablindedsecondreading.The
resulting intraobserver reliability coefﬁ-
cient was 0.96.
Outcome measures
Endothelialfunction. Endothelialfunc-
tion was measured as ﬂow-mediated dila-
tion (FMD), the percent change of
brachial artery diameter from before cuff
inﬂation to 60 s after cuff release. In ad-
dition to brachial diameter at 60 s after
cuff release, ﬂow after cuff deﬂation
within the ﬁrst 15 s was used as an indi-
cator of stimulus strength, hyperemic
ﬂowbeingthestimulusforendothelialre-
activity. To account for potential variabil-
ityinstimulusstrength,FMDwasdivided
byﬂowat15saftercuffdeﬂationtocreate
a stimulus-adjusted response measure.
Cardiovascular biomarkers. Fasting
serum lipids, fasting serum glucose, fast-
ing serum insulin, and plasma A1C were
measured at the Grifﬁn Hospital labora-
tory using standard procedures at each
visit. Homeostasis model assessment of
insulin resistance (HOMA-IR) values
were calculated (HOMA calculator ver-
sion 2.2.1) from fasting serum glucose
and serum insulin levels to gauge the de-
gree of insulin resistance.
Anthropometric measures. To mea-
sure weight, participants were asked to
remove their heavy outer garments
(jacket,coat,etc.)andshoes,andstandin
thecenteroftheplatformwithweightdis-
tributed evenly on both feet. BMI was cal-
culated using the weight and height
measurements. Waist circumference was
measured at the umbilicus with the mea-
surement tape surrounding the abdomen
horizontal to the ﬂoor.
Diet record analysis. Diet records were
analyzed using basic nutrition and diet
analysis software (The Food Processor II,
version 7.0; ESHA Research, Salem, OR).
Statistical analysis
Repeated-measures ANOVA was used to
assess differences in intraindividual re-
sponses across treatments. Paired t tests
were also used to compare baseline mean
values of all outcome measures among
participants by group assignment. A
Tukey test was used for post hoc analysis
of the repeated-measures ANOVA to cor-
rect for the experiment-wise error rate.
The combined effect of independent vari-
ables (age, race, BMI, hypertension, dys-
lipidemia, and treatment sequence) and
treatment assignment on all outcome
measures was assessed with multivariable
models with the use of ANOVA. All anal-
yses of end points were based on the in-
tention-to-treat principle. Statistical
signiﬁcance was set at two-tailed 
0.05. Data were analyzed with the use of
SAS software for Windows (version 9.1;
SAS Institute, Cary, NC). Results are ex-
pressed as means  SD in text and tables.
The sample size was determined to allow
for 20% attrition and noncompliance
and to provide 80% power to detect a
minimal difference of 2.5% in FMD be-
tween treatments with maximum allow-
able type I error of 5%.
RESULTS
Subject characteristics
Twenty-one of the 24 participants who
began treatment completed the study.
Three participants dropped out because
of changes in medications or poor com-
pliance with the treatment protocol. The
mean age of participants who completed
the study was 58 years; 58% of subjects
were women. The mean baseline diame-
ter of the brachial arteries was 4.2 mm,
andthemeanabsolutechangeindiameter
was 0.3 mm. Mean baseline endothelial
functionmeasuredasFMDwas8.6%.De-
mographic and baseline characteristics
are shown in Table 1.
Endothelial function
FMD improved signiﬁcantly after con-
sumption of the walnut-enriched diet as
compared with consumption of an ad li-
bitumdietwithoutwalnuts(2.21.7vs.
1.2  1.6%, P  0.04). No signiﬁcant
change was seen in the stimulus-adjusted
response measure (P  0.05).
Serum lipids
After consumption of a walnut-enriched
diet,serumtotalcholesterolandLDLcho-
lesteroldecreasedsigniﬁcantlyfrombase-
line (9.7  14.5 mg/dl, P  0.01 and
7.7  10.0 mg/dl, P  0.01, respec-
tively). However, the improvement did
not reach statistical signiﬁcance com-
pared with consumption of an ad libitum
diet without walnuts (P  0.05). Serum
triglycerides and HDL cholesterol did not
improve after consumption of a walnut-
enriched diet (Table 2).
Fasting serum glucose, serum
insulin, plasma A1C, HOMA-IR
Thewalnut-enricheddietsigniﬁcantlyin-
creased fasting serum glucose from base-
line (10.0  20.5 mg/dl, P  0.04), but
the difference was not signiﬁcant (P 
0.05) compared with that for the ad libi-
tum diet without walnuts. Fasting serum
insulin, plasma A1C, and HOMA-IR did
not change signiﬁcantly (P  0.05) after
consumption of the walnut-enriched diet
(Table 2).
Blood pressure
Theadlibitumdietwithoutwalnuts(con-
trol) signiﬁcantly lowered blood pressure
compared with the walnut-enriched diet
(systolic blood pressure 4.9  11.7 vs.
4.0  9.2 mmHg, P  0.01; diastolic
blood pressure 2.5  6.4 vs. 1.6  4.6
mmHg, P  0.02).
Anthropometric measures
BMI,weight,andwaistcircumferencedid
not change after consumption of the wal-
nut-enriched diet (Table 2).
Dietary intake and compliance
Dietary intakes of PUFAs, n-3 fatty acid,
and n-6 fatty acid increased signiﬁcantly
with the walnut-enriched diet compared
withthosewithanadlibitumdietwithout
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P  0.01; n-3 fatty acid 5.84  0.86 vs.
0.81  0.45 g, P  0.01; and n-6 fatty
acid 26.02  4.43 vs. 6.17  3.10 g, P 
0.01). Dietary intake of other nutrients
remained stable throughout the study
(Table 3). According to participants’ re-
portsandrecountsofemptywalnutpack-
ages, 96% of study subjects complied
with walnut ingestion (deﬁned as con-
sumption of 80% of the assigned
amount of walnuts) during treatment.
CONCLUSIONS — This study dem-
onstrated that consumption of an ad libi-
tum diet enriched with 56 g walnuts/day
for 8 weeks signiﬁcantly improved endo-
thelial function in this sample of type 2
diabetic individuals. These results are
consistent with results of previous trials
demonstrating that ingestion of walnuts
improved endothelial function in hyper-
cholesterolemic adults (9) and reversed
postprandial endothelial dysfunction re-
sulting from a high-fat diet (10).
In addition to having a favorable fatty
acid proﬁle consisting of monounsatu-
rated fatty acids (MUFAs) and PUFAs,
nuts are also a rich source of bioactive
compoundswithbeneﬁcialeffectsoncar-
diovascular artery disease risk, including
dietary ﬁber, folate, and antioxidants.
Walnuts differ from other nuts because
they contain a high content of -linolenic
acid, which might confer additional anti-
atherogenic and antiarrhythmic proper-
ties. The mechanism by which walnuts
may improve endothelial function has
been hypothesized to involve increased
membrane ﬂuidity of endothelial cells,
thus promoting release of nitric oxide
(10) or to involve the role of vascular cell
adhesion molecule-1, whose levels may
be reduced by a walnut-rich diet, leading
to attenuated endothelial activation (9). A
walnut feeding experiment in an animal
model also showed a reduction in the ex-
pression of endothelin-1, a potent endo-
thelial activator (12). L-Arginine and
antioxidants in walnuts also may play a
role in improving vascular reactivity.
Although reductions of total and LDL
cholesterol were observed in the walnut-
enriched diet compared with baseline,
they were not signiﬁcant compared with
the ad libitum diet without walnuts. Pre-
vious trials examining the effect of walnut
ingestiononlipidproﬁlesreportedmixed
results. Some trials (13,14) did not ob-
serve signiﬁcant decreases in total choles-
terol and LDL cholesterol after ingestion
of walnuts. However, some have found
improvements in total and LDL choles-
terol resulting from the addition of wal-
nuts to the diets of hypercholesterolemic
or normolipidemic patients (15). Given
the variability in the results of these trials,
it remains unclear whether walnut con-
sumption improves cholesterol levels and
at what dose and in which population a
Table 1 —Demographic and baseline values before to initial treatment assignment
Age (years) 58.1  9.2
Women 14 (58.3)
Men 10 (41.7)
Diabetes medication use* 20 (83.3)
Lipid-lowering medication use† 13 (54.2)
Blood pressure–lowering medication use‡ 17 (70.8)
Baseline diameter (mm) 4.2  0.8
Absolute change in diameter (mm) 0.3  0.1
FMD (%) 8.6  4.3
Stimulus-adjusted response measure 0.08  0.05
BMI (kg/m
2) 32.5  5.0
Weight (kg) 89.0  15.5
Waist circumference (cm) 103.1  11.3
Systolic blood pressure (mmHg) 133.2  14.0
Diastolic blood pressure (mmHg) 77.7  7.3
Mean blood pressure (mmHg) 105.4  9.9
Fasting serum glucose (mg/dl) 129.7  34.4
Serum insulin (mIU/ml) 15.6  12.4
Insulin resistance 2.1  1.5
Plasma A1C (%) 6.7  0.9
Serum total cholesterol (mg/dl) 183.4  38.9
Serum triglycerides (mg/dl) 123.6  67.0
Serum HDL cholesterol (mg/dl) 56.0  14.7
Serum LDL cholesterol (mg/dl) 102.9  32.4
Serum cholesterol–to-HDL cholesterol ratio 3.4  1.0
Data are means  SD or n (%). n  24. *Included metformin (n  18), glipizide (n  3), chlorpropamide
(n  1), sitagliptin (n  3), pioglitazone (n  5), and glyburide (n  3). †Included atorvastatin (n  5),
pravastatin (n  2), simvastatin (n  2), fenoﬁbrate (n  1), lovastatin (n  1), rosuvastatin (n  1), and
ezetimibe/simvastatin (n  1). ‡Included lisinopril (n  9), verapamil (n  1), irbesartan (n  1), atenolol
(n  1), metoprolol (n  2), valsartan (n  1), enalapril (n  1), hydrochlorothiazide/moexipril (n  1),
nadolol (n  1), and olmesartan (n  1).
Table 2 —Change in outcome measures from baseline
Walnut-enriched
ad libitum
Ad libitum diet
without walnuts P
FMD (%) 2.2  1.7* 1.2  1.6* 0.04
Stimulus-adjusted response measure 0.01  0.05 0.04  0.14 0.37
BMI (kg/m
2) 0.0  1.4 0.3  0.9 0.44
Weight (kg) 0.1  3.2 0.7  2.2 0.46
Waist circumference (cm) 0.0  6.1 0.3  4.1 0.87
Systolic blood pressure (mmHg) 4.0  9.2 4.9  11.7 0.01
Diastolic blood pressure (mmHg) 1.6  4.6 2.5  6.4 0.02
Mean blood pressure (mmHg) 2.8  6.2 3.7  8.4 0.01
Fasting serum glucose (mg/dl) 10.0  20.5* 2.9  21.5 0.27
Serum insulin (mIU/ml) 3.6  10.4 3.4  8.0 0.02
Insulin resistance 0.2  0.9 0.2  0.7 0.10
Plasma A1C (%) 0.0  0.3 0.0  0.3 0.85
Serum total cholesterol (mg/dl) 9.7  14.5* 4.5  23.0 0.38
Serum triglycerides (mg/dl) 1.9  48.3 8.2  43.4 0.48
Serum HDL cholesterol (mg/dl) 0.8  6.5 1.8  7.2 0.22
Serum LDL cholesterol (mg/dl) 7.7  10.0* 7.8  20.6 0.97
Serum cholesterol–to-HDL cholesterol 0.2  0.4 0.2  0.5 0.73
Data are means  SD. n  22. P values were obtained from repeated-measures ANOVA. *P  0.05 from
paired Student t test.
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founding factors in this study include the
concomitant use of lipid-lowering medi-
cations, elevated body weight, and the
variability inherent in an ad libitum diet.
This study showed that a walnut-
enriched ad libitum diet did not affect
body weight or BMI. This ﬁnding is con-
sistent with previous clinical studies
(16,17). Epidemiological evidence con-
sistently indicates that nut consumers
have lower BMIs than nonconsumers
(18).
The walnut-enriched diet signiﬁ-
cantly increased fasting serum glucose
compared with baseline levels, although
this increase was not signiﬁcant com-
pared with that for an ad libitum diet
without walnuts. Furthermore, the wal-
nut-enriched diet did not signiﬁcantly af-
fectfastingseruminsulin,plasmaA1C,or
HOMA-IR compared with those at both
baselineandwithanadlibitumdietwith-
out walnuts. These results are fairly con-
sistent with those from previous clinical
studies in diabetic subjects (8,19). Al-
though epidemiological studies have in-
dicated that higher intakes of MUFAs and
PUFAs are associated with improvements
in insulin sensitivity (3), clinical evi-
dence,includingthistrial,hasthusfarnot
been able to support the hypothesis.
However, acute feeding studies have
demonstrated the ability of nuts to lower
postprandial glycemia when eaten with
carbohydrates (20,21).
Interestingly, blood pressure de-
creased signiﬁcantly in those consuming
theadlibitumdietwithoutwalnuts,com-
pared with baseline values and values for
those consuming the walnut-enriched
diet. Few studies have evaluated the ef-
fects of walnuts or other nuts on blood
pressure, but most of these have found
either a beneﬁcial effect or no effect (22–
24). It is possible that the changes in
bloodpressureobservedinthistrialcould
have inﬂuenced the improvement in en-
dothelial function. It is unclear why, in
thisstudy,anadlibitumdietwithoutwal-
nuts, in essence, the subjects’ habitual
diet, was associated with reduced blood
pressure.
This study has several limitations.
The ad libitum diet without walnuts was
not standardized, which limits our ability
to determine effects found exclusively
with walnuts. Using subjects as their own
controls in the crossover study design
shouldhavemitigatedthisproblem,how-
ever. The ad libitum diet without walnuts
was not standardized on purpose to en-
sure the generalizability of our results to
the broader population of diabetic indi-
viduals, most of whom do not follow a
clinically controlled diet. Participants
were allowed to maintain the ad libitum
dietandstablemedicationdosesandonly
received diet consultation to adjust their
caloric intake to prevent weight gain dur-
ing the walnut intervention phase. There-
fore, we believe that the improved
endothelial function with sustained wal-
nutconsumptionthatweobservedwould
be sustained in conditions approximating
areal-worldsetting.Asthisistheﬁrstwal-
nut feeding study without a standardized
control diet, we feel that this study will
add a new dimension to the existing liter-
ature on the health beneﬁts of walnuts.
Limitations to the generalizability of our
study include the small sample size, lack
of geographic variation, and a predomi-
nance of white women in our sample. In
addition, we do not know how physical
activity or genetic factors may factor into
our results, nor do we know the effect of
varying duration of diabetes and medica-
tion use among our participants. It is also
worth noting that there was a consider-
able range of responses to the addition of
walnuts to the diet, with some partici-
pants experiencing little to no improve-
ment or even a reduction in endothelial
function and others experiencing sub-
stantial improvement.
Despiteitslimitations,thisstudypro-
vides evidence that regular walnut con-
sumption improves endothelial function
in type 2 diabetic individuals and may
therefore help reduce cardiovascular dis-
ease risk in this high-risk population. Be-
cause subjects did not follow a restricted
diet, these results may have broader ap-
plicability to the general population than
previous diet-controlled trials. Future re-
searchers should continue to investigate
the role of walnuts and other nuts on en-
dothelial function and blood lipids in
populations at risk for cardiovascular
disease.
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Data are averages  SD from one 3-day record for each dietary period.
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